Simnotrelvir/ritonavir

< Simnotrelvir

Simnotrelvir/ritonavir
Chemical structures of simnotrelvir (top) and ritonavir (bottom)
Combination of
SimnotrelvirSARS-CoV-2 3CLpro inhibitor
RitonavirProtease inhibitor
Clinical data
Trade names先诺欣 (Xiannuoxin)
Pregnancy
category
  • Contraindicated (CN)
Routes of
administration		Oral
Legal status
Legal status
  • Rx in China
Simnotrelvir
Clinical data
Other namesSIM0417, SSD8432
Routes of
administration		Oral
Drug classSARS-CoV-2 3CLpro inhibitor
Legal status
Legal status
  • Not approved on its own
Pharmacokinetic data
Protein binding72.5%
Metabolismhepatic (CYP3A)
Elimination half-life3.1 h; 4.1 h with ritonavir
Excretionurine (55.4%), feces (36.7%)
Identifiers
  • (8S)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-7-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxamide
PubChem CID
Chemical and physical data
FormulaC22H30F3N5O4S2
Molar mass549.63 g·mol−1
3D model (JSmol)
  • CC(C)(C)[C@@H](C(=O)N1CC2(C[C@H]1C(=O)N[C@@H](C[C@@H]3CCNC3=O)C#N)SCCS2)NC(=O)C(F)(F)F
  • InChI=InChI=1S/C22H30F3N5O4S2/c1-20(2,3)15(29-19(34)22(23,24)25)18(33)30-11-21(35-6-7-36-21)9-14(30)17(32)28-13(10-26)8-12-4-5-27-16(12)31/h12-15H,4-9,11H2,1-3H3,(H,27,31)(H,28,32)(H,29,34)/t12-,13-,14-,15+/m0/s1
  • Key:LQBRGTAIBBFUJJ-ZQDZILKHSA-N

Simnotrelvir/ritonavir (trade name Xiannuoxin) is a pharmaceutical drug used for the treatment of COVID-19. Simnotrelvir/ritonavir is a combination drug of simnotrelvir, an inhibitor of SARS-CoV-2 3CLpro, and ritonavir, a CYP3A inhibitor.

It was developed by Simcere Pharmaceutical and conditionally approved in China by the National Medical Products Administration (NMPA) in January 2023. Results for the phase Ib trial are available. In a phase II/III trial, it reduced the duration of symptoms by a median of 36 hours compared to placebo.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.